A 68 years old man with prostate carcinoma was referred for 68Ga-PSMA PET/CT scan because of recent significant rise of PSA. He complained of muscle weakness and fatigue, since 3 weeks before the scan, without dyspnea or shortness of breath. In his 68Ga-PSMA-611 PET/CT study, widespread skeletal metastasis, as well as liver involvement were noticed. Also, multiple bilatera...

OBJECTIVES: To evaluate the correlation between intensity of prostate specific membrane antigen (PSMA) expression by Gallium-68-PSMA positron emission tomography/computer tomography (Ga-68-PSMA PET/ CT) and D’Amico risk classification newly diagnosed cancer patients. MATERIALS AND METHODS: Retrospective reviews 61 patients, who underwent Ga-68-PSMA PET/CT September 2017 November 2021. Data maxi...

68Ga Prostate-specific membrane antigen (PSMA) is an increasingly popular radiopharmaceutical tracer in prostate cancer and is becoming increasingly researched in other cancers such as breast cancer, renal cell carcinoma, glioblastoma multiforme, among others. Cholangiocarcinoma is the second most common primary hepatic malignant tumor; it is an aggressive tumor with a 5-year surviva...

PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI. The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted US...

Abstract Background With increasing clinical demand for gallium-68, commercial germanium-68/gallium-68 ([ 68 Ge]Ge/[ Ga]Ga) generators are incapable of supplying sufficient amounts the short-lived daughter isotope. In this study, we demonstrate a high-yield, automated method producing multi-Curie levels [ Ga]GaCl 3 from solid zinc-68 targets and subsequent labelling to produce clinical-grade Ga...

BACKGROUND Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively sho...

The purpose of this study was to evaluate differences between patients receiving 18F-fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. Methods: All 68Ga-PSMA-11 PET studies performed the University California San Francisco from October 2015 January 2...

BACKGROUND Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro in order to get an insight of the interactions between altered premedicati...

A 73-year-old man with history of prostatic adenocarcinoma radical prostatectomy underwent 99mTc-MDP whole-body bone scan and subsequent 68Ga-labeled prostate-specific membrane antigen (PSMA) ligand PET/CT for restaging due to a gradual rise of prostate-specific antigen levels. Whole-body bone scan showed two focal zones of slightly increased uptake in the right fronto-par...